NAVIGEN, INC. — Department of Health and Human Services SBIR Phase I: NHLBI
NAVIGEN, INC. — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $268,075. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code NHLBI links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $268,075
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NHLBI
- Solicitation
- PA18-574
- NAICS
- —
- Place of performance
- UT
- Period
- 2019-09-24 → 2020-09-19
Description
SUMMARYInfluenzavirusinfectionisoneofthemostcommonacuterespiratorydiseasesandremainsoneofthelargestdiseaseburdensonhumanswithsevereprimaryviralpneumoniaoftenresultingindeathThepathogenicityofinfluenzaincludesahostresponsethatcanincludeaseveresystemicinflammatoryreactioncytokinestormandensuingvascularleakVascularleakisafundamentalelementinthepathogenesisofcirculatoryshockandmultipleorganfailurewhichcanleadtodeathininfluenzapatientsThelaboratoriesofDrDean Licofounder and former Chief Scientific Officer of Navigenand DrShannon Odelbergalong withNavigenhavedemonstratedthatvascularleakassociatedwithinflammationismediatedbyactivationofthesmall GTPaseARFa common nodal point in the signaling pathways of several inflammatory cytokines andgrowth factorsNavigen s objective is to reduce morbidity and mortality associated with influenza infections bymodifyingthishostresponseSpecificallyweproposetoevaluatetheefficacyofoursmallmoleculeARFinhibitorswiththehypothesisthatinhibitionofARFwillreducevascularleakelicitedbytheinfectionwhilehaving no adverse effect on immunitybased clearance of the virusNARRATIVEInfluenzainfectionremainsoneofthelargestdiseaseburdensonhumanswithsevereprimaryviralpneumoniaoftenresultingindeathThepathogenicityincludesahostresponsethatcanincludeaseveresystemicinflammatoryreactionandensuingvascularleakNavigenhasdemonstratedthatvascularleakassociated with inflammation is mediated by activation of the small GTPase ARFand proposes to evaluate itssmallmolecule ARFinhibitors in a mouse model of H Ninfection